SIGA Technologies commercializes TPOXX (tecovirimat), the first FDA-approved antiviral specifically for smallpox, with additional approvals for mpox and other orthopoxvirus infections in multiple countries. The company supplies oral and intravenous formulations to the U.S. Strategic National Stockpile and international government and public health customers. Its focus remains on developing medical countermeasures for serious infectious disease threats.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 81.1 | — | 35.5 | — |
| Q3 2025 | 2.6 | — | -6.4 | — |
| Q4 2025 | 3.8 | — | -5.4 | — |
| Q1 2026 | 6.2 | — | -3.5 | — |
| Q2 2026 | 41 | -49.5% | 12.5 | -64.9% |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: U.S. Gold Corp. (USAU), AIRO Group Holdings, Inc. (AIRO), AerSale Corporation (ASLE), Mercator Acquisition Corp. (MRCO), Etoiles Capital Group Co., Ltd (EFTY), Duos Technologies Group, Inc. (DUOT)